Literature DB >> 1190592

Pathogenesis of tularemia in immune and nonimmune rats.

J B Moe, P G Canonico, J L Stookey, M C Powanda, G L Cockerell.   

Abstract

Pathogenesis of tularemia in nonimmune rats given (intraperitoneal inoculation) virulent strain (SCHU S4) or vaccinal strain (LVS) of Francisella tularensis and in immune rats given SCHU S4 is described. Both LVS and SCHU S4 caused pyogranulomas in liver and spleen of nonimmune rats. Nonimmune rats given 10(4) SCHU S4 organisms did not survive beyond 72 hours, but immune rats given challenge inoculum of 10(8) SCHU S4 organisms developed lesions and survived. Larger doses of LVS resulted in earlier onset of characteristic hepatitis and splenitis in nonimmune rats. Periportal lymphocytic infiltrates were present in the liver 48 hours after SCHU S4 challenge inoculation of immune rats and 96 hours after inoculation of LVS in nonimmune rats and were associated with intense macrophage aggregation. These changes indicate that the pathogenesis of tularemia is a result of the interdependency of the dose and virulence of the causative agent with the immune status of the host and that cellular immunity has a significant role in the response of the rat to tularemia.

Entities:  

Mesh:

Year:  1975        PMID: 1190592

Source DB:  PubMed          Journal:  Am J Vet Res        ISSN: 0002-9645            Impact factor:   1.156


  11 in total

1.  Genetic identification of unique immunological responses in mice infected with virulent and attenuated Francisella tularensis.

Authors:  Luke C Kingry; Ryan M Troyer; Nicole L Marlenee; Helle Bielefeldt-Ohmann; Richard A Bowen; Alan R Schenkel; Steven W Dow; Richard A Slayden
Journal:  Microbes Infect       Date:  2010-11-09       Impact factor: 2.700

2.  Modifying effects of exercise on clinical course and biochemical response of the myocardium in influenza and tularemia in mice.

Authors:  N G Ilbäck; G Friman; W R Beisel; A J Johnson; R F Berendt
Journal:  Infect Immun       Date:  1984-08       Impact factor: 3.441

3.  In Vivo Intradermal Delivery of Bacteria by Using Microneedle Arrays.

Authors:  Alison J Scott; Robert K Ernst; Courtney E Chandler; Erin M Harberts; Tim Laemmermann; Qin Zeng; Belita N Opene; Ronald N Germain; Christopher M Jewell
Journal:  Infect Immun       Date:  2018-08-22       Impact factor: 3.441

4.  Virulence of Francisella spp. in chicken embryos.

Authors:  Eli B Nix; Karen K M Cheung; Diana Wang; Na Zhang; Robert D Burke; Francis E Nano
Journal:  Infect Immun       Date:  2006-08       Impact factor: 3.441

5.  Respiratory tularemia: comparison of selected routes of vaccination in Fischer 344 rats.

Authors:  J V Jemski
Journal:  Infect Immun       Date:  1981-12       Impact factor: 3.441

6.  Sequential metabolic alterations in the myocardium during influenza and tularemia in mice.

Authors:  N G Ilbäck; G Friman; W R Beisel; A J Johnson
Journal:  Infect Immun       Date:  1984-08       Impact factor: 3.441

7.  Differential alterations in host peripheral polymorphonuclear leukocyte chemiluminescence during the course of bacterial and viral infections.

Authors:  J P McCarthy; R S Bodroghy; P B Jahrling; P Z Sobocinski
Journal:  Infect Immun       Date:  1980-12       Impact factor: 3.441

8.  Vaccination of Fischer 344 rats against pulmonary infections by Francisella tularensis type A strains.

Authors:  Terry H Wu; Jason L Zsemlye; Gloria L Statom; Julie A Hutt; Ronald M Schrader; Alexandra A Scrymgeour; C Rick Lyons
Journal:  Vaccine       Date:  2009-06-09       Impact factor: 3.641

9.  Neutrophils are critical for host defense against primary infection with the facultative intracellular bacterium Francisella tularensis in mice and participate in defense against reinfection.

Authors:  A Sjöstedt; J W Conlan; R J North
Journal:  Infect Immun       Date:  1994-07       Impact factor: 3.441

Review 10.  A brief, highly selective history of acute phase proteins as indicators of infection, inflammation and injury.

Authors:  Michael C Powanda; Elizabeth D Moyer
Journal:  Inflammopharmacology       Date:  2021-05-21       Impact factor: 4.473

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.